Sanofi expands rare disease pipeline with $2.2bn Inhibrx acquisition

23 Jan 2024
www.pmlive.com
Phase 2Clinical ResultAcquisition
Sanofi has announced that it will be acquiring clinical-stage biopharmaceutical company Inhibrx and its alpha-1 antitrypsin deficiency (AATD) candidate for approximately $2.2bn.
Sanofited to affect 80,000 to 100,000 people in the US, AATD is an inherited rare diseasInhibrxcterised alpha-1 antitrypsin deficiency (AATD)alpha-1 antitrypsinT protein, which protects the lungs and liver from inflammation.
As a result, patients are at an increased risk of develoAATD pulmonary disease, defined by progressive loss of lung tissue and function.inflammation
Inhibrx’s INBRX-101 is a human recombinant protein that workspulmonary diseaseutrophil elastase, an enzyme responsible for lung tissue damage in AATD patients.
InhibrxdidINBRX-101s the promise” of allowing AATD patients to achieve normaneutrophil elastaseAT levels with less frequent (monthly versus weeklAATDosing, Sanofi said, adding that it could also help to reduce inflammation and prevent further deterioration of lung function.
INBRX-101 has already completed an early-stage study, which demonstrated positive results in tAATs of safety and pharmacokinetics. A phase 2 trial to furtheSanofiuate its potential in AATD has also started enroinflammationts.
INBRX-101hrafian, head of research and development at Sanofi, said: “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commitAATDdifferentiated and potential best-in-class products.
“… INBRX-101 will complement our approach to deploy reSanofi and development efforts INBRX-101eas of focus and address the needs of the underserved AATD patients and communities.”
InhINBRX-101 spin off its non-INBRX-101 assets, including its immuno-oncology pipeline, into a newly formed entity, New Inhibrx. This will continue AATDperate under the Inhibrx name.
Inhibrxhe terms of the agreemeINBRX-101i will acquire all outstanding shares of Inhibrx for $30 per share in cash, rNew Inhibrx an equity value of approximately $1.7bn. Inhibrx’s shareholders will also receive one contingent value right equal to $5 and 0.25 shares of New Inhibrx per Inhibrx share.
The announcement comes less than tSanofiths after Sanofi and artificial intelligInhibrxI) specialist Aqemia entered into a multi-year research collaboration worth $140m Inhibrxover small molecule drug candidates across several therapeutic areas.New InhibrxInhibrx
The company also partnered with BioMap, another AISanofialist, last October to accelerate drug discovAqemiar biotherapeutics, with the deal potentially worth over $1bn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.